We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · August 26, 2020

Reduced Mortality and Adverse Events With Pioglitazone for T2D and Advanced CKD

Diabetes Care

 

Additional Info

Diabetes Care
Pioglitazone Reduces Mortality and Adverse Events in Patients With Type 2 Diabetes and With Advanced Chronic Kidney Disease: National Cohort Study
Diabetes Care 2020 Aug 14;[EPub Ahead of Print], CL Yen, CY Wu, LC See, YJ Li, MH Tseng, WS Peng, JR Liu, YC Chen, TH Yen, YC Tian, CW Yang, GF Anderson, HY Yang

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading